A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Recruiting
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland +1 locations
Conditions: Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Recruiting
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products (Faricimab and Port Delivery System with Ranibizumab) in approved retinal indications (neovascular age-related macular degeneration... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: Cumberland Valley Retina Consultants PC, Hagerstown, Maryland
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Recruiting
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding pa... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
11/03/2023
Locations: Hagerstown, MD, Hagerstown, Maryland
Conditions: Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A Study to Investigate RO7200220 in Diabetic Macular Edema
Recruiting
Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: Cumberland Valley Retina Consultants, Hagerstown, Maryland
Conditions: Diabetic Macular Edema
Evaluation of Tonabersat for DME
Recruiting
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: Elman Retina Group, Baltimore, Maryland
Conditions: Diabetic Macular Edema
4D-150 in Patients With Diabetic Macular Edema
Recruiting
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Gender:
All
Ages:
18 years and above
Trial Updated:
08/29/2023
Locations: Cumberland Valley Retina Consultants, Hagerstown, Maryland
Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT
Recruiting
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT The purpose of this study is to collect data on the NVHO device at up to three sites.
Gender:
All
Ages:
All
Trial Updated:
02/15/2023
Locations: Elman Retina Group, PA, Baltimore, Maryland
Conditions: Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME)
Recruiting
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: Cumberland Valley Retina Consultants, Hagerstown, Maryland
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema